Cancer can produce some miraculous phenomena, such as “mother and child suppression”. The earliest and largest cancer mass in human body is called “primary tumor” – mother foci; at this time, there may be tiny cancer foci in other parts of the body, which cannot be detected by instruments, called “daughter foci”. “The mother tumor is the largest tumor in volume. The mother foci have an inhibitory effect on the micro foci in other parts of the body, preventing them from growing. Once the primary mother foci are removed by surgery, this inhibitory effect between mother and child ceases to exist, and the invisible micro kid foci soon grow out. Studies at Harvard University, University of London, University of South Carolina and the National Institute of Oncology in Italy have shown that – the removal of the primary tumor can cause the spread of malignant tumors elsewhere (reference “Cancer Can Be Beaten – A Body and Mind Approach to Boosting the Body’s Ability to Fight Cancer A Mindful Approach” by DanKenner, USA). That is, keeping the primary cancer sites intact, rather than removing them surgically, may inhibit the development of malignant tumors elsewhere in the body. A report published by Carlos Arteaga, a professor at Vanderbilt University in Tennessee, and colleagues, from Reference News reports that “the phenomenon that anti-cancer therapies can lead to the resurgence and growth of cancer cells is generally recognized. Radiation therapy, chemotherapy and surgery have all led to cancer recurrence.” They may have found one of the causes, a compound known as TGF-β” (transforming growth factor-2″). Cancer experts suspect that the so-called primordial cancer cells – the first to appear and the largest in size – may somehow inhibit the growth of other cancer cells, and that removing or killing the primordial cancer cells may allow other, undetected cancer cells to grow. They speculate that TGF-β induced by anti-cancer therapies (surgery, radiation, chemotherapy) could act as a signal for cancer cell survival, allowing cancer cells to resist the effects of anti-cancer therapies and subsequently recur. TGF-β may be just the tip of the iceberg. I once saw a middle-aged male patient who had ultrasound and enhanced MRI to confirm the diagnosis of hepatocellular carcinoma in June 2012. Preoperative routine examination did not reveal lung metastasis, and cancerous mass was removed that month. Little did I know that 2 months later, routine review of liver enhancement MRI would reveal multiple recurrent cancer foci in the liver, multiple metastatic cancers in both lower lungs, and rapid growth of microscopic cancer foci in other areas after the considered surgery.